Mounjaro vs Saxenda: Price & Results Breakdown (2026)
Trying to choose between Mounjaro (Tirzepatide) and Saxenda (Liraglutide)? Below we put the trial weight loss numbers, monthly cost, dosing, and tolerability head to head — and spell out the type of patient each one tends to fit best.
Mounjaro (Tirzepatide, Dual GLP-1/GIP receptor agonist) and Saxenda (Liraglutide, GLP-1 receptor agonist) work through different mechanisms. Mounjaro is FDA-approved for type 2 diabetes with 15-22% of body weight average weight loss at $1,023/mo. Saxenda is approved for chronic weight management with 5-8% of body weight average weight loss at $1,350/mo.
The Numbers at a Glance
| Feature | Mounjaro | Saxenda |
|---|---|---|
| Active Ingredient | Tirzepatide | Liraglutide |
| Mechanism | Dual GLP-1/GIP receptor agonist | GLP-1 receptor agonist |
| FDA Approved For | Type 2 diabetes | Chronic weight management |
| Doses | 2.5mg to 15mg (weekly injection) | 0.6mg to 3mg (daily injection) |
| Administration | Weekly subcutaneous injection | Daily subcutaneous injection |
| Avg. Weight Loss | 15-22% of body weight | 5-8% of body weight |
| Monthly Price | $1,023 | $1,350 |
| Oral Available | No | No |
| Year Approved | 2022 | 2014 |
- Mounjaro
- Tirzepatide
- Saxenda
- Liraglutide
- Mounjaro
- Dual GLP-1/GIP receptor agonist
- Saxenda
- GLP-1 receptor agonist
- Mounjaro
- Type 2 diabetes
- Saxenda
- Chronic weight management
- Mounjaro
- 2.5mg to 15mg (weekly injection)
- Saxenda
- 0.6mg to 3mg (daily injection)
- Mounjaro
- Weekly subcutaneous injection
- Saxenda
- Daily subcutaneous injection
- Mounjaro
- 15-22% of body weight
- Saxenda
- 5-8% of body weight
- Mounjaro
- $1,023
- Saxenda
- $1,350
- Mounjaro
- No
- Saxenda
- No
- Mounjaro
- 2022
- Saxenda
- 2014
Figures shown are typical cash-pay prices before insurance. What you pay can differ by pharmacy, region, and your specific plan. Last updated March 2026.
Which Drops More Weight?
Based on clinical data, Mounjaro produces more weight loss on average (15-22% of body weight) compared to Saxenda (5-8% of body weight). Mounjaro relies on Tirzepatide (Dual GLP-1/GIP receptor agonist), whereas Saxenda uses Liraglutide (GLP-1 receptor agonist) — a likely reason for the gap.
The earliest medication to combine GLP-1 and GIP receptor activity. Indicated for type 2 diabetes and taken off-label for weight loss, it tends to produce larger reductions than semaglutide on its own.
Among the earliest GLP-1 therapies to win FDA clearance for weight loss. It calls for a shot every day, unlike the weekly schedule of newer drugs, and is steadily giving way to more potent alternatives.
Which Is Easier on Your Wallet?
At list price, Mounjaro is the more affordable option at $1,023/month compared to $1,350/month for Saxenda. That said, what leaves your pocket swings hugely with your coverage. Mounjaro with insurance: $25-$200/month with Lilly savings card. Saxenda with insurance: Varies widely.
Eligible patients may qualify for the Eli Lilly savings card
A manufacturer savings card is available
How the Side Effects Stack Up
Mounjaro (Dual GLP-1/GIP receptor agonist) and Saxenda (GLP-1 receptor agonist) bring on much the same digestive side effects, which top the list of what patients report:
- Nausea (most common for both medications)
- Diarrhea and vomiting
- Constipation
- Abdominal pain
- Decreased appetite
- Headache, fatigue, dizziness (less common)
Rarer but more serious risks for both drugs include pancreatitis, gallbladder complications, and kidney strain. Each also carries a boxed warning about medullary thyroid carcinoma seen in rodent studies. Go over your complete medical history with a clinician before you start either one.
So Which One Is Right for You?
There is no single winner — the right pick comes down to your diagnosis, what your plan covers, how much weight you want to lose, and how you feel about injections versus pills. Use the quick checklist below as a starting point:
- -You have type 2 diabetes (on-label use, better insurance coverage)
- -Cost is a concern ($1,023/month at list price)
- -You want the dual GLP-1/GIP mechanism for potentially greater efficacy
- -You prefer the convenience of once-weekly dosing
- -Your primary goal is weight loss (FDA-approved indication)
- -You prefer a daily dosing routine
- -Your doctor recommends Liraglutide based on your health profile
See Who Prescribes These at the Lowest Price
Browse vetted telehealth programs that can prescribe Mounjaro, Saxenda, and other FDA-approved GLP-1 medications — ranked by what you will actually pay.
Common Questions, Answered
Can I switch from Mounjaro to Saxenda?
It can be done, but only under a prescriber's guidance, since Mounjaro and Saxenda rely on different active ingredients (Tirzepatide vs Liraglutide). Your clinician will set the right starting dose and titration plan for whichever medication you move to.
Which is better for weight loss: Mounjaro or Saxenda?
Clinical data suggests Mounjaro produces more weight loss on average (15-22% of body weight) compared to Saxenda (5-8% of body weight). However, individual results vary significantly based on dosing, diet, exercise, and metabolic factors.
Is Mounjaro cheaper than Saxenda?
At list price, Mounjaro ($1,023/month) is less expensive than Saxenda ($1,350/month). With insurance, costs vary significantly. Mounjaro: $25-$200/month with Lilly savings card. Saxenda: Varies widely.
Do Mounjaro and Saxenda have the same side effects?
They overlap a lot. Stomach-related effects like nausea, diarrhea, vomiting, and constipation show up with both because they are typical of GLP-1 receptor agonists. That said, the different active ingredients mean how often and how strongly they hit can differ — talk through your history with a clinician to see which is the safer fit for you.
Does insurance cover Mounjaro and Saxenda?
Coverage varies by plan. Mounjaro is FDA-approved for type 2 diabetes — insurance coverage is typically better for on-label use. Saxenda is FDA-approved for chronic weight management. Check with your specific insurance plan and ask your doctor about prior authorization requirements.